Aurstat
Commercial- Indications
- Atopic dermatitis, Eczema, Skin irritation, Minor burns, Lacerations, Abrasions
Company intelligence / Profile preview
Onset marketed a portfolio of prescription dermatology products based on proprietary foam and hydrogel technologies. Clinical results included significant reduction of itch in atopic dermatitis patients using Aurstat® Hydrogel. The company’s pipeline included both marketed products and investigational drugs for acne and other skin disorders.
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Onset Dermatologics.